title: CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
abstract: OBJECTIVE
  This study investigated factors associated with chorioretinal atrophy (CRA) progression in myopic choroidal neovascularization (CNV) after anti-vascular endothelial growth factor therapy.
  
  
  METHODS
  Fifty eyes of 50 treatment-naive patients with myopic CNV who underwent anti-vascular endothelial growth factor monotherapy with at least 2 years of follow-up data were included. The cumulative occurrence of CRA progression was assessed using a Kaplan-Meier analysis. Demographic and clinical characteristics including macular choroidal thickness in various areas were compared between patients with and without CRA progression.
  
  
  RESULTS
  The mean age was 52.34 years. A mean of 4.84 anti-vascular endothelial growth factor injections were performed over the mean follow-up duration of 44.6 months. Eventually, 15 eyes (30%) developed CRA progression. The estimated occurrence of CRA progression was 10% at 1 year, 19.1% at 2 years, 23.6% at 3 and 4 years, and 35.4% at 5 years. Chorioretinal atrophy progression was associated with a subfoveal CNV location (P = 0.029) and thinner subfoveal choroid in relation to the inferior choroid at 3 mm (P = 0.008). Visual improvement was only significant in eyes without CRA progression at 1 year, 2 years, and at the final visit.
  
  
  CONCLUSIONS
  Chorioretinal atrophy progression was associated with a poor long-term prognosis. Relative thinning of the subfoveal choroid about the inferior choroid and subfoveal CNV location may predispose eyes with myopic CNV to develop CRA progression after anti-vascular endothelial growth factor therapy.
authors: Department of Ophthalmology, The Institute of Vision Research, Yonsei University College of Medicine, Seoul, South Korea.
authors: Ji Hwan
authors: JH
authors: Lee
authors: Sung Chul
authors: SC
authors: Lee
authors: Seo Hee
authors: SH
authors: Kim
authors: Hyoung Jun
authors: HJ
authors: Koh
authors: Sung Soo
authors: SS
authors: Kim
authors: Suk Ho
authors: SH
authors: Byeon
authors: Christopher Seungkyu
authors: CS
authors: Lee
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D001284:Atrophy / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D000068258:Bevacizumab / Q000008:administration & dosage*; D002829:Choroid / Q000473:pathology*; D020256:Choroidal Neovascularization / Q000175:diagnosis* / Q000209:etiology; D018450:Disease Progression; D005260:Female; D005451:Fluorescein Angiography / Q000379:methods; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications* / Q000175:diagnosis; D000069579:Ranibizumab / Q000008:administration & dosage*; D012164:Retinal Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D012189:Retrospective Studies; D013997:Time Factors; D041623:Tomography, Optical Coherence / Q000379:methods; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab